



Complete Summary

GUIDELINE TITLE

Procedure guideline for extended scintigraphy for differentiated thyroid cancer.

BIBLIOGRAPHIC SOURCE(S)

Society of Nuclear Medicine. Procedure guideline for extended scintigraphy for differentiated thyroid cancer. Reston (VA): Society of Nuclear Medicine; 1999 Feb. 15 p. (Society of Nuclear Medicine procedure guidelines; no. 2.0). [5 references]

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY

SCOPE

DISEASE/CONDITION(S)

Thyroid Cancer

GUIDELINE CATEGORY

Diagnosis
Evaluation

CLINICAL SPECIALTY

Nuclear Medicine
Radiology

INTENDED USERS

Allied Health Personnel
Physicians

GUIDELINE OBJECTIVE(S)

To assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of extended scintigraphy for differentiated thyroid cancer.

TARGET POPULATION

Patients with thyroid cancer

INTERVENTIONS AND PRACTICES CONSIDERED

- Iodine-131 scintigraphy
- Scintigraphy with other radiopharmaceuticals, including iodine-123, thallium-201, and technetium-99m sestamibi

MAJOR OUTCOMES CONSIDERED

Sensitivity for detection of thyroid cancer.

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Literature searches were performed. In addition, references known to experts and references from the nuclear medicine community were considered.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Drafts of the guideline were submitted to members of the Guideline Development subcommittee (methodologists) and the Task Force (subject experts). These reviewers indicated on a line-by-line basis any suggestions or recommendations for the revision of the guideline. The percentage of agreement for all reviewers was calculated for each revision and compiled by the Society of Nuclear Medicine (SNM) central office. It is expected that the percentage of agreement will increase with each revision.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

When the Task Force and Guideline Development Subcommittee completed their edits, draft procedure guidelines were distributed to the Society of Nuclear Medicine (SNM) Sample Review Group for comment. (The SNM Sample Review Group is a cross-section of approximately 100 nuclear medicine practitioners representing every field of specialization).

The guideline was approved by the SNM Commission on Health Care Policy, the Board of Directors, and the House of Delegates.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Background Information and Definitions

Scintigraphy for detection of thyroid metastasis and/or residual functioning thyroid tissue consists of obtaining images of the body, 2-6 days following the oral ingestion of I-131. Other radiopharmaceuticals such as I-123, Tl-201 and Tc-99m

sestamibi may also provide useful information, but their effectiveness has not been established.

Common Indications

To determine the presence and location of residual functioning thyroid tissue and/or functioning thyroid cancer.

Procedure

The detailed procedure recommendations in the guideline address the following areas: patient preparation; information pertinent to performing the procedure (i.e., important data that the physician should have about the patient at the time the exam is performed and interpreted); precautions; information regarding the radiopharmaceutical (i.e., ranges of administered activity, organ receiving the largest radiation dose, effective dose), image acquisition; interventions; processing; interpretation/reporting; quality control, and sources of error.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Not stated

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

The intent of the procedure guideline is to describe extended scintigraphy for differentiated thyroid cancer, in order to maximize the diagnostic information obtained in the study while minimizing the resources that are expended.

POTENTIAL HARMS

Not stated

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

The following issues requiring further clarification are identified in the guideline document:

- What is the best dose of I-131?

- The role of I 123 in whole-body surveys for metastatic disease should be considered, particularly considering the decreased stunning and radiation exposure associated with this isotope. The increased cost of a whole-body scanning dose of this isotope must also be considered.
- How important is compliance with a strict low iodine diet?
- Lithium administration may promote retention of radioiodine in metastatic foci.

The Society of Nuclear Medicine has written and approved guidelines to promote the cost-effective use of high quality nuclear medicine procedures. These generic recommendations cannot be applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures or exclusive of other procedures reasonably directed to obtaining the same results. The spectrum of patients seen in a specialized practice setting may be quite different than the spectrum of patients seen in a more general practice setting. The appropriateness of a procedure will depend in part on the prevalence of disease in the patient population. In addition, the resources available to care for patients may vary greatly from one medical facility to another. For these reasons, guidelines cannot be rigidly applied.

Advances in medicine occur at a rapid rate. The date of a guideline should always be considered in determining its current applicability.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness
Safety

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Society of Nuclear Medicine. Procedure guideline for extended scintigraphy for differentiated thyroid cancer. Reston (VA): Society of Nuclear Medicine; 1999 Feb. 15 p. (Society of Nuclear Medicine procedure guidelines; no. 2.0). [5 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Feb

GUIDELINE DEVELOPER(S)

Society of Nuclear Medicine, Inc - Medical Specialty Society

SOURCE(S) OF FUNDING

Society of Nuclear Medicine (SNM)

GUIDELINE COMMITTEE

Guideline Task Force

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

The Task Force consists of members from both academic and nonacademic practice settings.

Names of Task Force Members: David Backer, MD; David Brill, MD; Kevin Donogoe, MD; Howard Dworkin, MD; Robert Hattner, MD; and Roberta Locko, MD.

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously issued version (Procedure guideline for extended scintigraphy for differentiated thyroid cancer: 1.0. Society of Nuclear Medicine. J Nucl Med 1996 Jul;37[7]:1269-71.)

The guideline developer states that the guideline is subject to a bi-annual update/revision cycle.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [Society of Nuclear Medicine \(SNM\) Web site](#).

Print copies: Available from SNM, Division of Health Care Policy, 1850 Samuel Morse Dr, Reston, VA 20190-5316; Phone: 1-800-513-6853 or 1-703-326-1186; Fax: 703-708-9015; E-Mail: ServiceCenter@snm.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- Society of Nuclear Medicine. Procedure guideline for guideline development. Reston (VA): Society of Nuclear Medicine; 2001 Jun (version 3.0).

Electronic copies: Available from the [Society of Nuclear Medicine Web site](#).

- Society of Nuclear Medicine. Performance and responsibility guidelines for NMT. Reston (VA): Society of Nuclear Medicine; 2003.

Electronic copies: Available from the [Society of Nuclear Medicine Web site](#).

Print copies: Available from SNM, Division of Health Care Policy, 1850 Samuel Morse Dr, Reston, VA 20190-5316; Phone: 1-800-513-6853 or 1-703-326-1186; Fax: 703-708-9015; E-Mail: ServiceCenter@snm.org.

NGC STATUS

This summary was completed by ECRI on May 20, 1999. It was verified by the guideline developer as of May 26, 1999.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For further information, please contact Marie Davis at the Society of Nuclear Medicine, telephone (703) 708-9000, ext. 250.

© 1998-2004 National Guideline Clearinghouse

Date Modified: 11/8/2004

FIRSTGOV

